BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Morley KC, Lagopoulos J, Logge W, Chitty K, Baillie A, Haber PS. Neurometabolite Levels in Alcohol Use Disorder Patients During Baclofen Treatment and Prediction of Relapse to Heavy Drinking. Front Psychiatry 2018;9:412. [PMID: 30233431 DOI: 10.3389/fpsyt.2018.00412] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
Number Citing Articles
1 Tsermpini EE, Plemenitaš Ilješ A, Dolžan V. Alcohol-Induced Oxidative Stress and the Role of Antioxidants in Alcohol Use Disorder: A Systematic Review. Antioxidants (Basel) 2022;11:1374. [PMID: 35883865 DOI: 10.3390/antiox11071374] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
2 Napolitano A, Longo D, Lucignani M, Pasquini L, Rossi-Espagnet MC, Lucignani G, Maiorana A, Elia D, De Liso P, Dionisi-Vici C, Cusmai R. The Ketogenic Diet Increases In Vivo Glutathione Levels in Patients with Epilepsy. Metabolites 2020;10:E504. [PMID: 33321705 DOI: 10.3390/metabo10120504] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
3 Chen T, Tan H, Lei H, Su H, Zhao M. Proton magnetic resonance spectroscopy in substance use disorder: recent advances and future clinical applications. Sci China Inf Sci 2020;63:170101. [DOI: 10.1007/s11432-019-2818-5] [Cited by in Crossref: 2] [Article Influence: 0.7] [Reference Citation Analysis]
4 Morley KC, Lagopoulos J, Logge W, Baillie A, Adams C, Haber PS. Brain GABA levels are reduced in alcoholic liver disease: A proton magnetic resonance spectroscopy study. Addict Biol 2020;25:e12702. [PMID: 30561840 DOI: 10.1111/adb.12702] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
5 Farokhnia M, Browning BD, Leggio L. Prospects for pharmacotherapies to treat alcohol use disorder: an update on recent human studies. Curr Opin Psychiatry 2019;32:255-65. [PMID: 31107292 DOI: 10.1097/YCO.0000000000000519] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 5.3] [Reference Citation Analysis]
6 Castrén S, Mäkelä N, Alho H. Selecting an appropriate alcohol pharmacotherapy: review of recent findings. Curr Opin Psychiatry 2019;32:266-74. [PMID: 30973369 DOI: 10.1097/YCO.0000000000000512] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
7 Hillemacher T, Frieling H. Pharmacotherapeutic options for co-morbid depression and alcohol dependence. Expert Opinion on Pharmacotherapy 2019;20:547-69. [DOI: 10.1080/14656566.2018.1561870] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
8 de Beaurepaire R, Sinclair JMA, Heydtmann M, Addolorato G, Aubin HJ, Beraha EM, Caputo F, Chick JD, de La Selle P, Franchitto N, Garbutt JC, Haber PS, Jaury P, Lingford-Hughes AR, Morley KC, Müller CA, Owens L, Pastor A, Paterson LM, Pélissier F, Rolland B, Stafford A, Thompson A, van den Brink W, Leggio L, Agabio R. The Use of Baclofen as a Treatment for Alcohol Use Disorder: A Clinical Practice Perspective. Front Psychiatry 2018;9:708. [PMID: 30662411 DOI: 10.3389/fpsyt.2018.00708] [Cited by in Crossref: 38] [Cited by in F6Publishing: 35] [Article Influence: 7.6] [Reference Citation Analysis]